Human Genome Sciences Soon to Be Part of Samsung Biologics

Samsung Biologics’ wholly owned U.S. subsidiary, Samsung Biologics America, signed a definitive agreement to acquire Human Genome Sciences from GSK. The move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint, and its long-term commitment to the U.S. market, according to a company spokesperson.

Located in Rockville, MD, the facility sits at the center of one of the key U.S. bioclusters and encompasses two cGMP manufacturing plants with a combined 60,000 L of drug substance capacity, supporting both clinical and commercial production from small to large scale. Existing products will continue to be manufactured at the site, and Samsung Biologics says it plans to make additional investments to expand the site’s capacity and upgrade technology to further support a more resilient U.S. supply chain for critical biologic medicines.

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for $280 million. The company reports that it will also retain more than 500 employees at the site to ensure operational continuity and stability.

Samsung Biologics completed its Bio Campus I and II, and also recently secured land for Bio Campus III, which will house distinct R&D and manufacturing programs for new modalities. With 785,000 L of capacity across five plants, the industry’s leading capacity, Samsung Biologics maintains that it will continue to advance its diversified portfolio spanning monoclonal antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies.

“This marks an important step forward in our mission to achieve a better life through biomedicines,” said John Rim, CEO, Samsung Biologics. “We look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact.”

“Along with GSK’s recent commitment to invest $30bn in R&D and manufacturing in the U.S. over the next five years, this deal enables us to further focus on building the agility, capacity, and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines,” added Regis Simard, president, global supply chain, GSK.

The post Human Genome Sciences Soon to Be Part of Samsung Biologics appeared first on GEN - Genetic Engineering and Biotechnology News.